Experimental CAR-T therapy targets tough lymphoma in small safety trial
NCT ID NCT07447726
First seen Mar 12, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This early-phase study tests a new type of CAR-T cell therapy (CD19X) in 3 people with relapsed or refractory large B-cell lymphoma, a blood cancer that has not responded to standard treatments. The main goal is to check safety, looking for side effects like cytokine release syndrome and nerve problems. Researchers will also measure how well the treatment shrinks tumors and how long the CAR-T cells stay in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.